Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,704.00
(
-0.39%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
113.88
(
6.85%
)
Bitcoin
70,197.37
(
-1.47%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 94189

Wednesday, 04/14/2010 9:51:57 PM

Wednesday, April 14, 2010 9:51:57 PM

Post# of 257257

Gammagard [phase-3] trial #1 still enrolling (18 months duration); assume trial #1 to report Jan 2012

Mid 2012 is probably more realistic—see http://www.marketwatch.com/story/baxter-issues-update-on-gammagard-phase-iii-trial-2010-04-14 .

Thanks for your continuing commentary on the AD landscape.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now